14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $68.49 $68.49 Friday, 27th Jan 2023 GBT stock ended at $68.49. During the day the stock fluctuated 0% from a day low at $68.49 to a day high of $68.49.
90 days $68.49 $68.49
52 weeks $21.65 $73.02

Historical GLOBAL BLOOD THERAPEUTICS prices

Date Open High Low Close Volume
Sep 12, 2019 $54.62 $54.97 $53.19 $54.31 646 430
Sep 11, 2019 $51.10 $54.55 $50.60 $54.20 815 870
Sep 10, 2019 $50.34 $51.36 $49.79 $51.36 754 508
Sep 09, 2019 $50.25 $50.99 $48.55 $50.70 788 273
Sep 06, 2019 $53.46 $53.72 $50.25 $50.32 1 332 594
Sep 05, 2019 $54.45 $56.50 $52.45 $52.66 3 284 663
Sep 04, 2019 $46.54 $47.56 $46.01 $47.49 773 627
Sep 03, 2019 $45.87 $47.06 $45.18 $45.89 695 502
Aug 30, 2019 $46.84 $47.51 $45.96 $45.98 524 670
Aug 29, 2019 $47.70 $48.08 $46.53 $46.70 633 606
Aug 28, 2019 $45.28 $47.65 $44.75 $46.88 2 049 297
Aug 27, 2019 $47.54 $47.89 $45.24 $45.35 1 171 375
Aug 26, 2019 $45.86 $47.29 $45.34 $47.13 485 508
Aug 23, 2019 $46.89 $47.22 $45.09 $45.36 522 914
Aug 22, 2019 $46.62 $47.66 $46.62 $47.14 739 966
Aug 21, 2019 $47.09 $47.17 $46.21 $46.75 597 786
Aug 20, 2019 $47.68 $48.18 $46.14 $46.85 656 585
Aug 19, 2019 $48.92 $49.12 $47.42 $48.07 675 960
Aug 16, 2019 $47.15 $48.19 $46.45 $48.02 692 024
Aug 15, 2019 $48.02 $48.10 $46.58 $46.68 596 087
Aug 14, 2019 $47.23 $49.28 $47.11 $48.14 692 712
Aug 13, 2019 $48.91 $50.75 $47.77 $48.40 873 986
Aug 12, 2019 $48.28 $49.12 $47.57 $48.85 460 776
Aug 09, 2019 $49.06 $49.95 $47.82 $48.79 556 599
Aug 08, 2019 $49.30 $49.66 $46.72 $49.57 717 714
Click to get the best stock tips daily for free!

About GLOBAL BLOOD THERAPEUTICS

GLOBAL BLOOD THERAPEUTICS Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, ... GBT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT